Skip to main content
TipRanks
Go Ultimate75% OFF

Fortrea Holdings Inc. (FTRE) Drug Pipeline

118 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Geh300079 (68Ga) Injection Positron-Emission Tomography (Pet)/Computed Tomography (Ct)Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancers, Ovarian Cancersphase2AndPhase3Not Yet RecruitingStudy to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)Oct 09, 2025
D3s-001Healthy Adult VolunteersPhase IRecruitingA Phase 1 Study to Assess Food Effect on the Pharmacokinetics of D3S-001 in Healthy Adult ParticipantsJul 10, 2025
Ap301, Ap301 Low DoseChronic Kidney Disease, Receiving Dialysis, Esrd (End-Stage Renal Disease), Hyperphosphatemia, DialysisPhase IIIRecruitingA Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and ChinaMar 19, 2025
Givinostat Hydrochloride, Givinostat Hydrochloride - Cohort 2Duchenne Muscular DystrophyPhase IIRecruitingPharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years OldDec 11, 2024
Ath-1105Healthy VolunteersPhase ICompletedA SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105May 17, 2024―
Geh200520 Injection And Geh200521 (18F) Injection, Static - Pet/Ct ScanHealthy VolunteersPhase IRecruitingA Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy VolunteersApr 23, 2024
GivinostatDuchenne Muscular DystrophyPhase IIIRecruitingEfficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular DystrophyJun 16, 2023
Altropane (123I) InjectionMovement Disorders, Parkinson DiseasePhase IITerminatedAltropane Dose for Imaging Patients With Suspected Parkinson's DiseaseNov 01, 2022―
LeniolisibApdsPhase IIIActive Not RecruitingPediatric Patients Aged 1 to 6 Years With APDSOct 17, 2022―
LeniolisibApdsPhase IIIActive Not RecruitingPediatric Patients Aged 4 to 11 Years With APDSMay 20, 2022―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Fortrea Holdings Inc. (FTRE) have in its pipeline
Fortrea Holdings Inc. FTRE is currently developing the following drugs: Geh300079 (68Ga) Injection Positron-Emission Tomography (Pet)/Computed Tomography (Ct), D3s-001, Ap301, Ap301 Low Dose, Givinostat Hydrochloride, Givinostat Hydrochloride - Cohort 2, Ath-1105, Geh200520 Injection And Geh200521 (18F) Injection, Static - Pet/Ct Scan, Givinostat, Altropane (123I) Injection, Leniolisib, Vit-2763 120 Mg, Vit-2763 360 Mg, Vit-2763 240 Mg, Rivaroxaban, Abelacimab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.